The current financial score of Relay Therapeutics Inc is 5.79. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 350.00K, representing a year-over-year decrease of 48.30%, while its net profit experienced a year-over-year decrease of 18.94%.
The current valuation score of Relay Therapeutics Inc is 8.52. Its current P/E ratio is -12.05, which is -92.45% below the recent high of -0.91 and -10.14% above the recent low of -13.27.
The current earnings forecast score of Relay Therapeutics Inc is 8.71. The average price target is 26.75, with a high of 32.00 and a low of 20.00.
The current price momentum score of Relay Therapeutics Inc is 4.11. Currently, the stock price is trading between the resistance level at 20.42 and the support level at 17.61, making it suitable for range-bound swing trading.
The current institutional shareholding score of Relay Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 101.48%, representing a quarter-over-quarter increase of 3.47%. The largest institutional shareholder is James Simons, holding a total of 192.40K shares, representing 0.00% of shares outstanding, with 45.08% decrease in holdings.
The current risk assessment score of Relay Therapeutics Inc is 6.33. The company's beta value is 1.76. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.